Medical devices, healthcare technology and the business of care
PMA decision · P230015

Access HBsAg, Access HBsAg Confirmatory, Access HBsAg Calibrator, Access HBsAg QC

BECKMAN COULTER, INC. · Decision date Oct 17, 2025

FDA DECISIONP230015

What did the FDA decide?

FDA records P230015 as an original PMA application. The recorded decision is APRL, dated Oct 17, 2025.

FDA approval order statement

Approval for the Access HBsAg, Access HBsAg Confirmatory, Access HBsAg Calibrator, Access HBsAg QCAccess HBsAg The Access HBsAg assay is a paramagnetic particle, chemiluminescent immunoassay for the in vitro qualitative detection of hepatitis B surface antigen (HBsAg) in human pediatric (7 through 21 years) and adult serum and serum separator tubes or plasma [lithium heparin, lithium heparin separator tubes, dipotassium (K2) EDTA, tripotassium (K3) EDTA, sodium citrate, acid citrate dextrose (ACD), and citrate phosphate dextrose (CPD)] using the DxI 9000 Access Immunoassay Analyzer.The Access HBsAg assay is used for the laboratory diagnosis of acute or chronic hepatitis B virus (HBV) infection in individuals with signs and symptoms of hepatitis or at risk for hepatitis B virus infection, when used in conjunction with other serological and clinical information. The assay may also be used to screen for HBV infection in pregnant women to identify neonates who are at risk of acquiring hepatitis B during the perinatal period.The Access HBsAg assay is for use on the DxI 9000 Access Immunoassay Analyzer only.This assay has not been approved for use in the screening of blood, plasma, or tissue donors or cadaveric specimens.ACCESS HBsAg CALIBRATOR The Access HBsAg Calibrator is intended to calibrate the Access HBsAg and Access HBsAg Confirmatory assays for the in vitro qualitative detection and confirmation of hepatitis B surface antigen (HBsAg) in human serum and plasma using the DxI 9000 Access Immunoassay Analyzer.For additional information, refer to the Access HBsAg and Access HBsAg Confirmatory reagent Instructions for Use.ACCESS HBsAg QC The Access HBsAg QC is intended for monitoring system performance of the Access HBsAg and Access HBsAg Confirmatory assays. The Access HBsAg QC is for use on the DxI 9000 Access Immunoassay Analyzer.For additional information, refer to the Access HBsAg and Access HBsAg Confirmatory reagent Instructions for Use.ACCESS HBsAg CONFIRMATORYHepatitis B Virus Surface AntigenThe Access HBsAg Confirmatory assay is a paramagnetic particle, chemiluminescent immunoassay for the in vitro qualitative confirmation of the presence of hepatitis B surface antigen (HBsAg) in human pediatric (7 through 21 years) and adult serum and serum separator tubes or plasma [lithium heparin, lithium heparin separator tubes, dipotassium (K2) EDTA, tripotassium (K3) EDTA, sodium citrate, acid citrate dextrose (ACD), and citrate phosphate dextrose (CPD)] that have been found to be repeatedly reactive in the Access HBsAg assay using the DxI.
Regulatory pathway
Original PMA
Clinical specialty
Microbiology
Decision date
Oct 17, 2025

FDA source record

Regulatory record facts

Identifier
P230015
Regulatory pathway
Premarket approval application
Product code
LOM
Decision code
APRL
Decision date
Oct 17, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen).

Product code
LOM
FDA device class
2

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P230015 received

    Application receipt date recorded by FDA.

  2. P230015 · FDA decision

    APRL

Timeline entries are records held by MedtechLedger for P230015. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code LOM

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

BECKMAN COULTER, INC.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
250 S. Kraemer Blvd., Brea, CA, 92821

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records